institute of experimental haematology and transfusion medicine

• A service of the DFG , the HRK and the DAAD

German Research Institutions

• Institute of Experimental Haematology and Transfusion Medicine
• Doctoral programmes
• Institutions

Projekts / Doctoral Opportunities

Venusberg-Campus 1, 53127 Bonn

Affiliated institutions

• Bonn Center for Dependency and Slavery Studies
• Bonn Center for Digital Humanities
• Bonn Centre for Teacher Training (BZL)
• Center for Comparative Theology and Social Issues (CTSI)
• Center for Science and Thought (CST)
• Collegium musicum
• Digital Science Center (DiCe)
• Faculty of Protestant Theology
• Exzellenzcluster PhenoRob
• Graduate Schools
• University Sports Office
• Institute of Law in the Water and Waste Industry (IRWE)
• Interdisciplinary centres
• Faculty of Catholic Theology
• Cultural Forum
• Käte Hamburger Centre for Advanced Study "Law as Culture"
• Faculty of Agriculture
• Faculty of Mathematics and Science
• Neuromodulation of Emotion (NEMO) Research Group
• Institute of Anatomy
• Bonn Technology Campus
• Surgical Centre
• Institute of Innate Immunity
• Institute of Biochemistry and Molecular Biology (IBMB)
• Institute of Experimental Epileptology and Cognition Research (IEECR)
• Institute of Experimental Immunology
• Institute of Experimental Oncology
• Institute for Genomic Statistics and Bioinformatics
• Institute of General Practice and Family Medicine
• Institute of Human Genetics
• Institute of Hygiene and Public Health
• Institute of Clinical Chemistry and Clinical Pharmacology
• Institute of Medical Biometry, Medical Informatics, and Epidemiology
• Institute of Medical Microbiology, Immunology and Parasitology
• Institute of Molecular Medicine
• Institute of Molecular Psychiatry
• Institute of Neuropathology
• Institute for Neurovascular Cell Biology
• Institute of Pathology
• Institute of Patient Safety (IfPS)
• Institute of Pharmacology and Toxicology
• Institute of Physiology I
• Institute of Physiology II
• Institute of Forensic Medicine
• Institute of Reconstructive Neurobiology
• Institute of Structural Biology
• Institute of Virology
• Institute of Cellular Neurosciences
• Institute for Cardiovascular Sciences
• Institute for Medical Humanities
• Clinic and Polyclinic for Dermatology and Allergology
• Clinic and Outpatient Clinic of Nuclear Medicine
• Clinic and Polyclinic for Palliative Medicine
• Radiological Clinic
• University Ophthalmology Clinic, Bonn
• Centre of Obstetrics and Gynaecology
• Centre for Internal Medicine
• Paediatrics Centre
• Centre of Dentistry, Oral Medicine and Kieferheilkunde
• Museums and Collections
• Faculty of Arts and Social Science
• Faculty of Law and Political Science
• Transdisciplinary Research Areas
• University and State Library
• University Hospital Bonn (UKB)
• Central academic facilities
• Centre for Historical Peace Research (ZHF)

Are you affiliated with this institution or do you represent it?

If you would like to request changes, please use our correction form.

Hemophilia: Training the immune system to be tolerant Hemophilia: Training the immune system to be tolerant

Study by the university of bonn elucidates an important immune mechanism.

Hemophilia A is the most common severe form of hemophilia. It affects almost exclusively males. The disease can usually be treated well, but not for all sufferers. A study at the University of Bonn has now elucidated an important mechanism that is crucial for making the therapy effective. The results could help better tailor treatment to patients. They have already been published online in a preliminary version; the final version will soon be published in the "Journal of Clinical Investigation."

Hemophilia A patients have a defect in a protein that is important for blood clotting: factor VIII. Most patients therefore receive an intravenous injection of the functional clotting factor every few days as treatment. But frequently, and especially at the start of treatment, the immune system recognizes the injected agent as foreign to the body and attacks it. This is the most serious complication of hemophilia treatment because factor VIII can then no longer work.

In these cases, immune tolerance therapy, which was also developed at the University Hospital Bonn (UKB) more than 40 years ago, often helps. This involves regularly injecting the hemophiliacs with a high dose of factor VIII over several months. The immune system thereby gets used to the injected protein and tolerates it. The underlying immune mechanisms are unknown. "However, this doesn't always work," explains Prof. Dr Johannes Oldenburg, Director of the Institute for Experimental Haematology and Transfusion Medicine at the UKB. "In about 30 percent of patients, tolerance induction does not lead to success. So your body's own defenses continue to attack and destroy the factor VIII protein, which means that factor VIII cannot be used for treatment. We wanted to know the reason for this."

To this end, the team looked at two cell types in the immune system, B cells and regulatory T cells. B cells recognize foreign molecules in the body and produce antibodies against them, which switch off the function of the molecule. For factor VIII, this means that it is no longer effective in hemophilia treatment.

Brake in the immune system

Regulatory T cells prevent an immune response from being too strong or lasting too long. The researchers have now found a new type among them that can act specifically against certain B cells rather than just non-specifically against all immune responses. "We were able to show that immunotolerance therapy results in the generation of regulatory T cells that exclusively induce B cells against factor VIII to commit suicide," says Dr. Janine Becker-Gotot of the Institute of Molecular Medicine and Experimental Immunology (IMMEI) at UKB. "These T cells have a sensor that allows them to recognize and attach to the corresponding B cells. In addition, they have the ability to push the self-destruct button on the surface of B cells."

This button is a molecule called PD-1. By activating it, it starts a program in the B cell that results in its death. Every active B cell has this button. "Our experiments enabled us for the first time to detect regulatory T cells that can activate this self-destruct button only in very specific B cells, in order to specifically prevent unwanted immune responses," explains IMMEI Director Prof. Dr. Christian Kurts.

The more PD-1 buttons the B cells against factor VIII carry on their surface, the easier it is for them to be driven to suicide by immune tolerance therapy. "The amount of PD-1 varies from person to person," Becker-Gotot explains. "If it's very low to begin with, there's a good chance that many inhibitor-producing B cells will survive and continue to neutralize the injected factor VIII."

Test to show in whom immunotolerance therapy is useful

Interestingly, B cells also produce more PD-1 once they come into contact with regulatory T cells. "We can now test how strong this reaction is," the researcher says. "If PD-1 levels go up shortly after starting immune tolerance therapy and then stay up, that's a clear sign that the treatment is going to be successful." The team is currently developing a blood test that can be used to detect whether or not immune tolerance therapy is working in patients during the prolonged treatment.

"Our findings have great basic scientific value," explains Prof. Kurts, who is a member of the Transdisciplinary Research Area "Life & Health" at the University of Bonn and, like Dr. Becker-Gotot and Prof. Oldenburg, a member of the Cluster of Excellence ImmunoSensation. "And not just for hemophilia, but also for other congenital disorders where missing proteins are replaced therapeutically. In the long term, they could also be used to develop new treatments." 

In addition to the IMMEI and the Institute of Experimental Haematology and Transfusion Medicine at the University Hospital Bonn, the IMC University of Applied Sciences in Krems (Austria) and the University of Melbourne (Australia) were involved in the study. The work was funded by the German Research Foundation (DFG), the University Hospital Bonn (Bonfor), a joint graduate college of the Universities of Bonn and Melbourne, the German National Academic Foundation (Studienstiftung des Deutschen Volkes) and the European "Innovative Medicines Initiative" (IMI).

Janine Becker-Gotot, Mirjam Meissner, Vadim Kotov, Blanca Jurado-Mestre, Andrea Maione, Andreas Pannek, Thilo Albert, Chrystel Flores, Frank A. Schildberg, Paul A. Gleeson, Birgit M. Reipert, Johannes Oldenburg, and Christian Kurts: Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ regulatory T cells; The Journal of Clinical Investigation; DOI: 10.1172/JCI159925

Dr. Janine Becker-Gotot Institute of Molecular Medicine and Experimental Immunology (IMMEI) University Hospital Bonn Phone: +49 228-287 11066 E-mail: [email protected]

Johannes Oldenburg

Professor Johannes Oldenburg, MD, is currently Director of the Institute of Experimental Haematology and Transfusion Medicine and of the Haemophilia Center, University Clinic Bonn. After receiving his medical degree, he has acquired numerous postdoctoral lecture qualifications, as well as qualifying as a specialist of transfusion medicine, and medical genetics. Since 1995, Johannes Oldenburg’s research has been focused on the molecular genetics of blood coagulation factors, with a focus on hemophilia, and the vitamin K pathway (discovery of VKORC1, the target of cumarins). Johannes Oldenburg is author of more than 300 publications in these fields. Johannes Oldenburg has received numerous scientific awards. He is a reviewer for most journals in the field of hemostasis, sits on the editorial boards for several high-impact journals, and is a member of directory boards for various associations.

The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH

Affiliations.

• 1 Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK.
• 2 Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
• 3 Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
• 4 van CreveldKliniek, UMC Utrecht, University Utrecht, Utrecht, the Netherlands.
• 5 Department of Vascular Medicine and Haemostasis, Haemophilia Centre, University Hospitals Leuven, Leuven, Belgium.
• 6 Centre for Bleeding Disorders, Department of Oncology, Careggi University Hospital, Florence, Italy.
• 7 Department of Pediatric Hematology, Academic Medical Centre, Amsterdam, the Netherlands.
• PMID: 30430726
• DOI: 10.1111/jth.14315

Publication types

• Research Support, Non-U.S. Gov't
• Hematologic Tests / standards*
• Hemophilia A / blood
• Hemophilia A / classification
• Hemophilia A / diagnosis*
• Hemophilia A / drug therapy*
• Hemostasis / drug effects*
• Hemostasis / genetics
• Hemostatics / adverse effects
• Hemostatics / therapeutic use*
• Predictive Value of Tests
• Terminology as Topic*
• Hemostatics